Samer Sayyed, MD
Internal Medicine · Omaha, NENPI 1972786929
Payments from drug & device makers
Across 27 payments — averaging $133.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$2K
- Heartflow, Inc.$1K
- Boston Scientific$155
- Abbott$144
- Lantheus Medical Imaging, Inc.$14
- Medtronic$11
What the payments were for
- Travel & lodging$2,48069%
- Food & beverage$1,13631%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 9 | $1,986 |
| Heartflow, Inc. | 8 | $1,305 |
| Boston Scientific | 2 | $155 |
| Abbott | 6 | $144 |
| Lantheus Medical Imaging, Inc. | 1 | $14 |
| Medtronic | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,616 in reported general payments places this provider in the 85th percentile of 570 internal medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 112 | $148,427 |
| JardianceEmpagliflozin | 120 | $145,674 |
| EliquisApixaban | 95 | $107,247 |
| Repatha SureclickEvolocumab | 79 | $49,566 |
| FarxigaDapagliflozin Propanediol | 42 | $46,810 |
| Praluent PenAlirocumab | 37 | $21,300 |
| VascepaIcosapent Ethyl | 21 | $9,827 |
| Atorvastatin Calcium | 432 | $3,389 |
| Metoprolol Succinate | 237 | $2,506 |
| Ezetimibe | 141 | $2,444 |
| Nebivolol Hcl | 14 | $1,470 |
| Carvedilol | 201 | $1,332 |
| Lisinopril | 182 | $1,015 |
| Warfarin Sodium | 99 | $970 |
| Losartan Potassium | 119 | $854 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Omaha
- Michael DunnOmaha$7.9M
- Joel MichalskiOmaha$1.6M
- Ariana BauerOmaha$1.5M
- David CrockettOmaha$821K
- Bryant EnglandOmaha$637K
- Adam BurdorfOmaha$313K
- Brian BoerOmaha$142K
- David JasperOmaha$128K
- Andrew RorieOmaha$61K
- Mohamed AhmedOmaha$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.